Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents  

作　　者：Hao Wang Yu Yuan Bihao Wu Mingzhong Xiao Zhen Wang Tingyue Diao Rui Zeng Li Chen Yanshou Lei Pinpin Long Yi Guo Xuefeng Lai Yuying Wen Wenhui Li Hao Cai Lulu Song Wei Ni Youyun Zhao Kani Ouyang Jingzhi Wang Qi Wang Li Liu Chaolong Wang An Pan Xiaodong Li Rui Gong Tangchun Wu 

机构地区：[1]Ministry of Education and State Key Laboratory of Environmental Health(Incubating),School of Public Health,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [2]CAS Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China [3]University of Chinese Academy of Sciences,Beijing 100049,China [4]Affiliated Hospital of Hubei University of Chinese Medicine,Wuhan 430061,China [5]Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061,China

出　　处：《Frontiers of Medicine》2023年第4期747-757,共11页医学前沿（英文版）

基　　金：supported by the Emergency Key Program of Guangzhou Laboratory(No.EKPG21-30);the Fundamental Research Funds for the Central Universities(No.2019kfyXMBZ015);the Fellowship of China Postdoctoral Science Foundation(Nos.2020T130034ZX and 2020M680102);the National Natural Science Foundation of China(Nos.72061137006 and 82204113).

摘　　要：Emerging SARS-CoV-2 variants have made COVID-19 convalescents susceptible to re-infection and have raised concern about the efficacy of inactivated vaccination in neutralization against emerging variants and antigen-specific B cell response.To this end,a study on a long-term cohort of 208 participants who have recovered from COVID-19 was conducted,and the participants were followed up at 3.3(Visit 1),9.2(Visit 2),and 18.5(Visit 3)months after SARS-CoV-2 infection.They were classified into three groups(no-vaccination(n=54),one-dose(n=62),and two-dose(n=92)groups)on the basis of the administration of inactivated vaccination.The neutralizing antibody(NAb)titers against the wild-type virus continued to decrease in the no-vaccination group,but they rose significantly in the one-dose and two-dose groups,with the highest NAb titers being observed in the two-dose group at Visit 3.The NAb titers against the Delta variant for the no-vaccination,one-dose,and two-dose groups decreased by 3.3,1.9,and 2.3 folds relative to the wild-type virus,respectively,and those against the Omicron variant decreased by 7.0,4.0,and 3.8 folds,respectively.Similarly,the responses of SARS-CoV-2 RBD-specific B cells and memory B cells were boosted by the second vaccine dose.Results showed that the convalescents benefited from the administration of the inactivated vaccine(one or two doses),which enhanced neutralization against highly mutated SARS-CoV-2 variants and memory B cell responses.Two doses of inactivated vaccine among COVID-19 convalescents are therefore recommended for the prevention of the COVID-19 pandemic,and vaccination guidelines and policies need to be updated.

关 键 词：COVID-19 convalescent SARS-CoV-2 inactivated vaccination neutralizing antibody B cell response 

分 类 号：R392[医药卫生—免疫学]